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René Fuertig11, Ulrike Schmid11, Rainer-Georg Goeldner12, Natalja Strelkowa12, Dennis Chin-Lun Huang13, Thomas Bogenrieder14,15,
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BACKGROUND: Xentuzumab, an insulin-like growth factor (IGF)-1/IGF-2-neutralising antibody, binds IGF-1 and IGF-2, inhibiting
their growth-promoting signalling. Two first-in-human trials assessed the maximum-tolerated/relevant biological dose (MTD/RBD),
safety, pharmacokinetics, pharmacodynamics, and activity of xentuzumab in advanced/metastatic solid cancers.
METHODS: These phase 1, open-label trials comprised dose-finding (part I; 3+ 3 design) and expansion cohorts (part II; selected
tumours; RBD [weekly dosing]). Primary endpoints were MTD/RBD.
RESULTS: Study 1280.1 involved 61 patients (part I: xentuzumab 10–1800mg weekly, n= 48; part II: 1000 mg weekly, n= 13); study
1280.2, 64 patients (part I: 10–3600mg three-weekly, n= 33; part II: 1000mg weekly, n= 31). One dose-limiting toxicity occurred;
the MTD was not reached for either schedule. Adverse events were generally grade 1/2, mostly gastrointestinal. Xentuzumab
showed dose-proportional pharmacokinetics. Total plasma IGF-1 increased dose dependently, plateauing at ~1000mg/week; at
≥450 mg/week, IGF bioactivity was almost undetectable. Two partial responses occurred (poorly differentiated nasopharyngeal
carcinoma and peripheral primitive neuroectodermal tumour). Integration of biomarker and response data by Bayesian Logistic
Regression Modeling (BLRM) confirmed the RBD.
CONCLUSIONS: Xentuzumab was well tolerated; MTD was not reached. RBD was 1000mg weekly, confirmed by BLRM.
Xentuzumab showed preliminary anti-tumour activity.
CLINICAL TRIAL REGISTRATION: NCT01403974; NCT01317420.
British Journal of Cancer https://doi.org/10.1038/s41416-020-0774-1
BACKGROUND
The insulin-like growth factor (IGF) signalling axis plays a role in
carcinogenesis and is associated with cancer progression, prog-
nosis, and treatment resistance.1 Consequently, therapeutic target-
ing of the IGF axis has been investigated in various human cancers,
with early strategies targeting the IGF type 1 receptor (IGF-1R)
using anti-IGF-1R monoclonal antibodies (mAbs) and IGF-1R
tyrosine kinase inhibitors (TKIs).2 So far, there has been limited
success with these agents, although this may reflect the lack of
validated predictive biomarkers to allow patient enrichment.3
Xentuzumab (BI 836845) is a fully humanised IgG1 mAb, which
binds IGF-1 and IGF-2 with high affinity and potently neutralises
proliferative and pro-survival signalling triggered by both ligands.4
This ligand-binding approach offers advantages over IGF-1R-targeted
therapies, as it inhibits the proliferative/anti-apoptotic effects of IGF-2
signalling through insulin receptor isoform A (INSR-A).5 Additionally,
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IGF-1/-2-neutralising mAbs have a lower potential for hyperglycae-
mia than IGF-1R/INSR TKIs, as they do not affect the metabolic
INSR isoform B.5 In preclinical models, xentuzumab showed potent
anti-proliferative effects against a range of cancer cell lines, and
demonstrated encouraging anti-tumour activity and a favourable
safety profile in vivo.4
Here, two first-in-human phase 1 studies were conducted in
parallel to explore two dosing schedules (administration once
weekly and every 3 weeks) to determine the maximum-tolerated
dose (MTD) and/or relevant biological dose (RBD) of intravenous
(IV) xentuzumab in patients with advanced solid cancers,
considering safety, anti-tumour activity, and pharmacokinetics
(PK)/pharmacodynamics (PD).
METHODS
Study design and patients
Study 1280.1 (NCT01403974), conducted in Taiwan (August 2011
to June 2016), and study 1280.2 (NCT01317420), conducted in the
UK (June 2011 to December 2015), were phase 1, open-label,
dose-escalation trials, each comprising two parts. Part I was a
dose-finding period and used a 3+ 3 dose-escalation design,
while part II evaluated expansion cohorts of patients with selected
tumour types. The primary objective of part I was to identify the
MTD of xentuzumab (or the RBD in the absence of an MTD). To
assess the optimal dosing schedule, xentuzumab was given
once weekly in study 1280.1 and every 3 weeks in study 1280.2.
The objectives of part II were to evaluate anti-tumour activity at
the MTD/RBD, and to further evaluate the safety and PK/PD of
xentuzumab.
Eligible patients (aged ≥ 18 years) had pathologically confirmed
advanced/metastatic solid tumours and had failed or were not
amenable to standard therapy. Patients were required to have
evaluable disease or at least one measurable lesion per Response
Evaluation Criteria in Solid Tumours version 1.1 (RECIST v1.1), an
Eastern Cooperative Oncology Group performance status of 0, 1, or
2, and adequate haematological, hepatic, and renal function. Patients
entering part II were required to have cytologically or histologically
confirmed disease from the Ewing sarcoma family of tumours or
peripheral primitive neuroectodermal tumours (pPNET; cohort 1) or
solid tumours suitable for biopsy (cohort 2). Key exclusion criteria
included active infectious disease, serious illness, or concomitant
disease considered by the investigator to be incompatible with the
protocol. Patients who had not recovered from toxicities related to
previous anti-cancer therapy (to a severity of grade 1 or less;
Common Terminology Criteria for Adverse Events version 4.03
[CTCAE v4.03]) were excluded, as were those with a history of
diabetes mellitus or untreated/symptomatic brain metastases.
Treatment
In part I, patients received xentuzumab by 1-h IV infusion, either
weekly (study 1280.1; days 1, 8 and 15) or every 3 weeks (study
1280.2; day 1). The starting dose was 10 mg, and this dose was
doubled until CTCAE grade ≥2 drug-related adverse events (AEs)
occurred. Thereafter, dose escalations used incremental steps
equivalent to 20–50% of the previously evaluated dose. In part II
of both studies, patients were treated weekly at the MTD/RBD
determined in part I. Treatment continued until disease progres-
sion, clinically unacceptable AEs, or other reasons necessitating
withdrawal.
In the event of a dose-limiting toxicity (DLT), treatment could be
delayed for up to 4 weeks, and supportive therapy continued or
initiated (see Supplementary Methods for further information on
DLT criteria). In patients with documented clinical benefit (stable
disease [SD] or objective response [complete response (CR) or
partial response (PR)]), xentuzumab could be resumed at a
reduced dose level (maximum of two dose reductions), after
events had recovered to the baseline severity or CTCAE grade 1.
Endpoints and assessments
The primary endpoint in part I was the MTD/RBD. The MTD was
defined as the highest dose level of xentuzumab at which no
more than 1/6 patients experienced a DLT during the first 21-day
cycle. If the MTD was not reached, an RBD could be determined
using PK and biomarker data to infer target engagement; tumour
assessment data could also be considered.
AEs were graded according to CTCAE v4.03. Serial blood samples
were collected for determination of anti-drug antibodies (ADA) and
to determine plasma levels of xentuzumab and PD biomarkers
such as IGF-1, IGF-2, IGF binding protein 3 (IGFBP-3), and IGF-1R
phosphorylation. Ex vivo IGF-1R phosphorylation in a cellular assay
is considered a surrogate for IGF-1 and IGF-2 activity in patients’
plasma and will be referred to as ‘bioactive IGF’ throughout this
manuscript.6 Plasma samples were analysed for ADA using a
validated electrochemiluminescence method. Xentuzumab plasma
concentrations were determined using a validated enzyme-linked
immunosorbent assay (lower limit of quantification, 200 ng/mL).
Tumour assessment was performed according to RECIST v1.1 at
screening, every two cycles for the first six treatment cycles, and
every three cycles thereafter. Disease control was defined as CR/PR
or SD lasting ≥24 weeks. Analyses were descriptive and
exploratory; no formal statistical tests were performed.
Exploratory Bayesian logistic regression models (BLRMs),7,8 were
applied to confirm the RBD, using pooled data from all patients
who received weekly xentuzumab. A binary response criterion
(Yes/No) for each endpoint (saturation of total IGF-1 in plasma,
inhibition of IGF-bioactivity, and disease control) was assessed per
patient, to create input data for the BLRMs (Supplementary
Methods).
RESULTS
Patients and treatment
In total, 61 patients were treated in study 1280.1 (part I, n= 48;
part II, n= 13) and 64 patients in study 1280.2 (part I, n= 33;
part II, n= 31; Table 1; Supplementary Fig. S1). All patients in study
1280.1 were Asian and 97% of patients in study 1280.2 were white
(3% were Asian). All patients discontinued treatment, most
commonly due to progressive disease (study 1280.1, 77%; study
1280.2, 91%). In part I, patients received once-weekly xentuzumab
at 14 dose levels from 10 to 1800mg (study 1280.1), or every
3 weeks at 11 dose levels from 10 to 3600mg (study 1280.2).
During part II of both studies, patients received xentuzumab at the
RBD (1000 mg once weekly), determined via an integrated analysis
of safety, PK, biomarker and disease control data from both
studies. Treatment exposure is shown in Table 2.
DLTs and MTD
Only one DLT was observed (grade 3 pulmonary haemorrhage due
to bleeding from a vessel adjacent to the tumour in a patient with
follicular thyroid cancer [study 1280.1; xentuzumab 450mg/week;
Table 2]). In study 1280.1, dose escalation reached 1800 mg/week
without additional DLTs. No DLTs occurred with xentuzumab given
every 3 weeks (range 10–3600mg); consequently, the MTD was not
reached with either schedule. In the absence of an MTD, the
preliminary RBD (1000mg) was determined by combining data
from both phase 1 studies. An exploratory BLRM was conducted to
confirm the RBD (see below for further details).
Safety and tolerability
An overall summary of AEs and most common drug-related AEs for
xentuzumab given once weekly (study 1280.1) and every 3 weeks
(study 1280.2) is shown in Table 2. The most common AEs, regardless
of causality, were those pertaining to gastrointestinal disorders
(Supplementary Table S1). Most AEs were mild (CTCAE grade 1/2).
Grade ≥3 AEs occurred in 17 (part I) and 4 patients (part II) in study
1280.1, and in 16 (part I) and 10 patients (part II) in study 1280.2
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(Table 2). The most common drug-related AE across both studies was
nausea (mostly grade 1/2; study 1280.1: part I, one patient; study
1280.2: part I, four patients; part II, three patients; Table 2).
In study 1280.1, serious AEs (SAEs) were reported in 21 patients
(34%); only one was considered to be related to the study drug
(grade 3 pulmonary haemorrhage resulting in discontinuation; also
identified as a DLT). Twenty-four patients (38%) in study 1280.2 had
a SAE; in five, these were considered to be drug-related, as follows:
grade 2 infusion-related reaction (n= 2), grade 3 infusion-related
reaction, grade 3 hyperglycaemia, and grade 2 hypersensitivity
(each n= 1).
Five patients (8%) in study 1280.1 discontinued due to the
following AEs: pneumonia, metastases to the central nervous
system, pneumonia aspiration, pulmonary haemorrhage, and sub-
dural haemorrhage (all in part I). Three patients (5%) in study
1280.2 discontinued due to the following AEs: pneumonia
(part I), clostridium difficile colitis and infusion-related reaction
(both part II). Only grade 3 pulmonary haemorrhage (study 1280.1)
and grade 2 infusion-related reaction (study 1280.2) were considered
to be drug-related. Three patients had AEs that resulted in death
(acute respiratory failure [40mg weekly dose], dyspnoea [60mg
weekly dose], and malignant neoplasm progression [1800 mg weekly
dose]); all occurred in study 1280.1, part I, but none were considered
to be drug-related. The patients who had acute respiratory failure
and dyspnoea both had lung metastases at the start of treatment
and these AEs were associated with progression of their disease.
Immunogenicity
The immunogenic reaction to xentuzumab was low in both
studies. In study 1280.1, 5/235 ADA samples during part I and
0/103 ADA samples during part II had confirmed ADA-positive
results; however, most samples in part I and 85/103 samples in
part II were ADA-inconclusive due to low drug tolerance limits.
Overall, only 4/60 patients could reliably be determined as
ADA-negative, whereas 53 patients had to be defined as
ADA-negative but inconclusive. In study 1280.2, 7/115 ADA
samples in part I, and 1/108 ADA samples in part II had confirmed
ADA-positive results. However, 12/115 samples in part I and
72/108 samples in part II were ADA-inconclusive. Overall, only
15/64 patients could reliably be determined as ADA-negative,
whereas 43 patients had to be defined as ADA-negative but
inconclusive. ADA-positive and ADA-inconclusive patients did not
exhibit obvious differences in their PK and PD profiles compared
with confirmed ADA-negative patients (data not shown).
Table 1. Baseline characteristics.
Study 1280.1 (weekly xentuzumab)a
Part I
(n= 48)
Part II
(n= 13)
Total
(N= 61)
Male/female, n (%) 34 (71)/
14 (29)
4 (31)/
9 (69)
38 (62)/
23 (38)
Median age, years (range) 57.5 (19–76) 58.0 (29–72) 58.0 (19–76)
Race, n (%)
Asian 48 (100) 13 (100) 61 (100)
Black/African American 0 0 0
White 0 0 0
Baseline ECOG PS, n (%)
0 24 (50) 5 (38) 29 (48)
1 22 (46) 8 (62) 30 (49)
2 2 (4) 0 2 (3)
Type of cancer, n (%)b
Liver 7 (15) 1 (8) 8 (13)
Oesophagus 7 (15) 0 7 (11)
Colorectal 5 (10) 1 (8) 6 (10)
Soft tissue/osteosarcoma 3 (6) 2 (15) 5 (8)
Biliary tree 2 (4) 1 (8) 3 (5)
Endocrine cancers 3 (6) 0 3 (5)
Pleura 3 (6) 0 3 (5)
Thyroid and parathyroid 2 (4) 1 (8) 3 (5)
Endometrial cancer 0 2 (15) 2 (3)
Other 16 (33) 5 (38) 21 (34)
Prior anticancer therapy, n (%)
Systemic chemotherapy 43 (90) 13 (100) 56 (92)
Surgery 40 (83) 9 (69) 49 (80)
Molecular targeted therapy 10 (21) 0 10 (16)
Hormone therapy 3 (6) 0 3 (5)
Immunotherapy 2 (4) 0 2 (3)
Biological therapy 0 0 0
Other 32 (67) 5 (38) 37 (61)
Study 1280.2 (3-weekly xentuzumab)a
Part I
(n= 33)
Part II
(n= 31)
Total
(N= 64)
Male/female, n (%) 20 (61)/
13 (39)
20 (65)/
11 (35)
40 (63)/
24 (38)
Median age, years (range) 59.0 (23–79) 50.0 (19–77) 55.0 (19–79)
Race, n (%)
Asian 2 (6) 0 2 (3)
Black/African American 0 0 0
White 31 (94) 31 (100) 62 (97)
Baseline ECOG PS, n (%)
0 10 (30) 8 (26) 18 (28)
1 21 (64) 22 (71) 43 (67)
2 2 (6) 1 (3) 3 (5)
Type of cancer, n (%)b
Colorectal 6 (18) 6 (19) 12 (19)
Soft tissue/osteosarcoma 0 11 (35) 11 (17)
Adrenal 4 (12) 0 4 (6)
Ovary 2 (6) 2 (6) 4 (6)
GI tract 1 (3) 2 (6) 3 (5)
Oesophagus 1 (3) 2 (6) 3 (5)
Head and neck cancers 2 (6) 1 (3) 3 (5)
Lung 1 (3) 1 (3) 2 (3)
Table 1. continued
Study 1280.2 (3-weekly xentuzumab)a
Part I
(n= 33)
Part II
(n= 31)
Total
(N= 64)
Mesothelial cancers 1 (3) 1 (3) 2 (3)
NSCLC 2 (6) 0 2 (3)
Pancreas 2 (6) 0 2 (3)
Prostate 2 (6) 0 2 (3)
Other 9 (27) 5 (16) 14 (22)
Prior anticancer therapy, n (%)
Systemic chemotherapy 31 (94) 31 (100) 62 (97)
Surgery 23 (70) 24 (77) 47 (73)
Hormone therapy 4 (12) 1 (3) 5 (8)
Molecular targeted
therapy
4 (12) 0 4 (6)
Immunotherapy 1 (3) 0 1 (2)
Biological therapy 0 1 (3) 1 (2)
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Pharmacokinetics/pharmacodynamics
Non-compartmental PK parameters are summarised in Table 3.
Xentuzumab exhibited at least biphasic disposition kinetics in
both studies; after reaching the maximum, concentrations
declined rapidly during the initial 24-h period, and more slowly
thereafter. Exposure increased in proportion to the dose over both
dose ranges tested (10–1800 mg weekly; 10–3600mg every
3 weeks; Fig. 1a, Supplementary Fig. S2a). The geometric mean
terminal half-life across all dose groups was 6.7 days (range
5.2–9.1). Steady-state conditions were achieved after approxi-
mately 4–5 weeks in part I of both studies (weekly infusions:
31 days [range 9.5–51]; infusions every 3 weeks: 37 days). Weekly
dosing led to an accumulation ratio of approximately 1.5, based
on Cmax and AUC0–168 values, whereas no accumulation was
detected after repeated dosing every 3 weeks (study 1280.2,
part I). Geometric mean plasma concentration–time profiles in
part II (1000 mg/week) were similar between the two studies
(Fig. 1b, Supplementary Fig. S2b).
Total IGF-1, total IGF-2, total IGFBP-3 and bioactive IGF in plasma
were measured as markers of target engagement. Total IGF-1
concentrations increased dose dependently in both studies. With
weekly dosing, levels accumulated after repeated administration
(study 1280.1, part I; Fig. 1c), reaching a plateau at doses of
≥1050 mg/week (Fig. 1c, d). No plateau was reached by any of the
investigated doses administered every 3 weeks (Supplementary
Fig. S2c). The mean absolute change from baseline–time profile of
total IGF-1 in part II (1000 mg/week) was a similar shape and time
course in both studies, reaching a plateau after 4–5 weeks (Fig. 1e,
Supplementary Fig. S2d).
In both studies, IGF bioactivity declined rapidly after the start of
the xentuzumab infusion (Fig. 1f, Supplementary Fig. S2e). At
doses of ≥450mg/week, the median IGF bioactivity remained at
the limit of detection (LOD) for the entire dosing interval (Fig. 1f, g,
Supplementary Fig. S2f), while doses of up to 3600 mg given every
3 weeks did not reduce bioactive IGF to the same extent
(Supplementary Fig. S2e).
Table 2. Summary of exposure, overall safety summary and most common drug-related AEs (occurring in >2 patients in either study).
Study 1280.1 (weekly xentuzumab)a Study 1280.2 (3-weekly xentuzumab)a
Patients, n (%) Part I (n= 48) Part II (n= 13) Total (N= 61) Part I (n= 33) Part II (n= 31) Total (N= 64)
Exposure to xentuzumab treatment
Treatment duration, days, median (range) 43 (1–282) 78 (1–498) 57 (1–498) 22 (1–232) 36 (1–162) 26 (1–232)
Sum of treatment duration, years 10.2 5.0 15.2 3.7 4.4 8.1
Number of infusions, median (range) 6 (1–40) 12 (1–71) 9 (1–71) 2 (1–11) 6 (1–22) N/A
Overall AE summary
Any AE 46 (96) 12 (92) 58 (95) 33 (100) 31 (100) 64 (100)
Highest CTCAE grade AE
Grade 3 10 (21) 3 (23) 13 (21) 14 (42) 9 (29) 23 (36)
Grade 4 4 (8) 1 (8) 5 (8) 2 (6) 1 (3) 3 (5)
Grade 5 3 (6) 0 3 (5) 0 0 0
DLTb 1 (2) 0 1 (2) 0 0 0
Drug-related AE 10 (21) 2 (15) 12 (20) 14 (42) 15 (48) 29 (45)
AE leading to discontinuation 5 (10) 0 5 (8) 1 (3) 2 (6) 3 (5)
AE leading to dose reduction 0 0 0 0 0 0
Any SAE 17 (35) 4 (31) 21 (34) 9 (27) 15 (48) 24 (38)
Drug-related AEs, n (%)
Fatigue 0 0 0 3 (9) 4 (13) 7 (11)
Nausea 1 (2) 0 1 (2) 4 (12) 3 (10) 7 (11)
Lethargy 0 0 0 5 (15) 1 (3) 6 (9)
Decreased appetite 0 0 0 3 (9) 2 (6) 5 (8)
Diarrhoea 0 0 0 2 (6) 3 (10) 5 (8)
Constipation 0 0 0 3 (9) 0 3 (5)
Infusion-related reaction 0 0 0 0 3 (10) 3 (5)
Vomiting 1 (2) 1 (8) 2 (3) 0 1 (3) 1 (2)
Hyperglycaemia 0 0 0 1 (3) 1 (3) 2 (3)
Lymphocyte count decreased 2 (4) 0 2 (3) 0 0 0
Platelet count decreased 2 (4) 0 2 (3) 0 0 0
White blood cell count decreased 2 (4) 0 2 (3) 0 0 0
Anaemia 1 (2) 1 (8) 2 (3) 0 0 0
Neutropenia 0 0 0 0 2 (6) 2 (3)
Thrombocytopenia 0 0 0 0 2 (6) 2 (3)
Oral candidiasis 0 0 0 2 (6) 0 2 (3)
aIn part I, all doses (all patients in part II received xentuzumab 1000mg weekly).
bGrade 3 pulmonary haemorrhage due to bleeding from a vessel adjacent to tumour in 1 patient treated with xentuzumab 450mg weekly.
AE adverse event, CTCAE Common Terminology Criteria for Adverse Events, DLT dose-limiting toxicity, N/A not applicable, SAE serious adverse event.
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Fig. 1 PK and PD effects of xentuzumab in study 1280.1 (weekly xentuzumab). Mean plasma concentration–time profiles after IV infusion
of xentuzumab in part I course 1 (a; semi-log scale), and after the first (course 1) and repeated (course 2 and 3) weekly IV infusions of 1000mg
xentuzumab in part II (b; semi-log scale). Mean total IGF-1 absolute change from baseline–time profiles after repeated weekly xentuzumab
infusions in part I (c). Comparison of individual and arithmetic mean AUEC0-840 values of absolute change from baseline of total IGF-1 after
weekly xentuzumab infusions of 10–1800mg (d). Individual and arithmetic mean total IGF-1 absolute change from baseline–time profiles
after weekly IV infusion of 1000mg in part II (e; linear scale; filled circles indicate the mean values). Median bioactive IGF effect–time profiles
after repeated weekly infusions of xentuzumab in part I (f), and after weekly IV infusion of 1000mg in part II (g; linear scale). AUEC0–840 area
under the biomarker effect versus time curve between 0 and 840 h after the start of the first infusion, gMean geometric mean, IGF(-1) insulin-
like growth factor(-1), IV intravenous, PD pharmacodynamics, PK pharmacokinetics.
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No clear dose- or time-dependent effects of xentuzumab on
total IGF-2 and IGFBP-3 were detected in either study.
Anti-tumour activity
In part I of study 1280.1, two patients who received xentuzumab
once weekly at doses close to the RBD achieved durable PRs
(Table 4). The first (poorly differentiated nasopharyngeal carcinoma;
800mg) had a PR lasting 20.7 weeks (censored), and the second
(pPNET; 1050mg) had a PR lasting 30.4 weeks (censored); both
responses were detected first at the initial post-treatment assess-
ment, on days 42 and 41, respectively. Three patients in part I of
study 1280.1 achieved durable SD (≥24 weeks; urothelial carcinoma
[10mg], malignant mesothelioma [10mg], and cardiac adenocarci-
noma [600mg]), as did three patients in part II of study 1280.1 (all
1000mg; endometrial carcinoma, retroperitoneal leiomyosarcoma,
and thymic carcinoma). There were no objective responses in study
1280.2 (xentuzumab every 3 weeks); however, two patients in part I
of study 1280.2 (cervical adenocarcinoma [320mg] and prostate
adenocarcinoma [2400mg]) achieved durable SD.
Integration of biomarker and efficacy data (BLRM)
At the end of the study, all three endpoints for the BLRMs
indicated a dose-dependent increase of positive events, reaching
a plateau at around 1000mg, i.e. the probability of reaching the
RBD accumulated at around 1000mg (Supplementary Table S2).
The clearest signal was obtained from the saturation of total IGF-1
in plasma. Integrating all the data, the estimated posterior
probability of having reached the RBD at each weekly dose level
is shown in Fig. 2. The RBD was considered to have been reached
if the posterior probability was >80%; at 1000mg, this was 87%.
The RBD was confirmed to be 1000 mg weekly and was taken into
further clinical investigation in part II of studies 1280.1 and 1280.2,
and in new combination studies.
DISCUSSION
These two first-in-human trials established the RBD for xentuzu-
mab as 1000mg weekly IV; the MTD was not reached. The RBD
was determined based on an integrated analysis of available data
from both studies, including safety, PK, biomarker data, and
disease control. In study 1280.2, the 3-weekly schedule did not
show a similar level of target engagement at equivalent doses to
the weekly schedule; as such, xentuzumab 1000mg weekly was
assessed in the expansion part in both trials. At the end of the trial,
data integration performed using BLRMs was found to support the
previously determined RBD.
The safety profile of xentuzumab was clinically manageable and
tolerable, with only one DLT observed across both studies. AEs
were generally mild-to-moderate in intensity, the most common
pertaining to gastrointestinal disorders. Hyperglycaemia is a known
class effect of anti-IGF-1R mAbs and TKIs, despite their lack of
interference with insulin binding.1 The finding that drug-related
hyperglycaemia was rare with xentuzumab (no patients in study
1280.1 and two patients in study 1280.2 [grade 1 and grade 3]) is
consistent with clinical studies of another IGF-ligand blocking mAb,
dusigitumab (MEDI-573).9,10 The low incidence of hyperglycaemia
with xentuzumab suggests that the anti-ligand mechanism of
action may be more favourable than IGF-1R-targeted therapies with
regard to hyperglycaemia. The immunogenic reaction to xentuzu-
mab was low; however, no firm conclusions on ADA incidence and
prevalence could be made in either study due to a high frequency
of samples being deemed ADA inconclusive.
Xentuzumab showed dose-proportional plasma PK, with a mean
terminal half-life of 6.7 days, together with attainment of steady
state after 4–5 weeks. Accordingly, accumulation was moderate after
weekly infusions. No obvious differences in xentuzumab PK were
observed between the two phase 1 trials conducted in Europe and
Asia (geometric mean dose normalised parameters AUC0–168,norm
and Cmax,norm from course 1, part II of study 1280.2 [1000mg/week
dose] were within the range of corresponding values from different
weekly doses in study 1280.1).
Consistent with preclinical studies,11 increases in total IGF-1 and
a reduction in bioactive IGF in plasma demonstrated indirect and
direct target engagement, respectively. The increase in total IGF-1
is assumed to result from two mechanisms: (1) a reduced
elimination of IGF-1 following binding to xentuzumab; and (2) a
growth-hormone-dependent negative feedback mechanism via
the pituitary, which may increase IGF-1 secretion by the liver. The
plateau in total IGF-1 observed at 1050mg/week is hypothesised
to indicate that, at this dose, most IGF-1 in plasma is bound to
xentuzumab, and that the growth-hormone-dependent feedback
mechanism regulating IGF-1 secretion is saturated. No plateau in
total IGF-1 increase was reached with the investigated doses given
every 3 weeks. A reduction in IGF bioactivity to the LOD
throughout the dosing interval was observed with weekly doses
≥450mg. Infusions given every 3 weeks, even at the highest dose,
did not reduce bioactive IGF to the same extent. While
xentuzumab also neutralises IGF-2, no clear effects of xentuzumab
on total IGF-2 were detected in these phase 1 studies. We
hypothesise that this may be due to a lower binding affinity of
xentuzumab to IGF-2 than IGF-1, as well as a higher binding
affinity of IGF-2 to IGFBPs than IGF-1. IGF-2 synthesis is also
not affected by the growth-hormone-dependent feedback
mechanism. Nevertheless, there is evidence to suggest that free
(bioactive) IGF-2 was reduced through binding to xentuzumab.
Direct measurements of IGF-2 were not possible in the clinic;
however, bioactive IGF levels (surrogate for both IGF-1 and IGF-2
activity) decreased during xentuzumab treatment. Furthermore,
Table 4. Best overall response.
Study 1280.1 (weekly xentuzumab)a Study 1280.2 (3-weekly xentuzumab)a
Patients, n (%) Part I (n= 48) Part II (n= 13) Total (N= 61) Part I (n= 33) Part II (n= 31) Total (N= 64)
Best overall response
CR 0 0 0 0 0 0
PR 2 (4) 0 2 (3) 0 0 0
SDb 22 (46) 8 (62) 30 (48) 10 (30) 13 (42) 23 (36)
SD lasting ≥ 24 weeks 3 (6) 3 (23) 6 (10) 2 (6) 0 2 (3)
Progressive disease 20 (42) 3 (23) 23 (38) 21 (64) 11 (35) 32 (50)
NE 4 (8) 2 (15) 6 (13) 2 (6) 7 (23) 9 (14)
aIn part I (all patients in part II received xentuzumab 1000mg weekly).
bMeeting the minimum time of 35 days from first xentuzumab infusion.
CR complete response, NE not evaluable, PR partial response, SD stable disease.
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the effect of xentuzumab on free IGF-1 and IGF-2 was assessed in
a separate mechanistic PK-PD modelling study describing the
dynamics and interactions of IGF-1, IGF-2, and IGFBPs in the
absence and presence of xentuzumab.12 This quantitative frame-
work, developed by combining published in vitro and in vivo
information with clinical data from the xentuzumab phase 1
studies, enabled prediction of the concentrations of free IGF-1 and
IGF-2. Simulations indicated a high neutralisation of free IGF-1 and
IGF-2 over time (by at least 91% and 64%, respectively; steady
state versus baseline) at a xentuzumab dose of 1000mg/week.12
Xentuzumab showed preliminary anti-tumour activity in
pre-treated patients with advanced solid tumours, with two PRs
observed at doses close to the RBD (once weekly dosing) and
durable SD (≥24 weeks) reported in eight patients. These findings
are consistent with two phase 1 studies of dusigitumab, which
reported SD in Caucasian (US) and Asian (Japanese) patients.9,10
The results of the BLRM, integrating biomarkers (plateau in total
IGF-1; inhibition of IGF bioactivity), and efficacy data from patients
in both studies, provided further confirmation of the RBD. In the
BLRM model, the estimated probability of having reached the RBD
with a dose of 1000mg was 87%, indicating that saturation of
total IGF-1 biomarker, inhibition of IGF bioactivity, and disease
control would plateau around this dose.
While targeting of the IGF-1R pathway has been challenging,
with several failures in the clinical setting,13 we consider that the
distinct mechanism of action of xentuzumab (neutralisation of IGF
ligands) may offer advantages versus those previously employed
with IGF-1R mAbs and IGF-1R TKIs. Indeed, xentuzumab was
associated with a low incidence of hyperglycaemia compared with
anti-IGF-1R mAbs and TKIs. The favourable safety profile of
xentuzumab also offers the potential of combination with other
cancer therapies. Given the involvement of IGF signalling in
resistance to other anti-cancer therapies,1 this is a key area of
interest. It is also anticipated that inhibition of both IGF-1 and
IGF-2 may offer efficacy benefits over IGF-1R-targeted treatments
by also inhibiting proliferative signalling via IGF-2 activation of
INSR-A, but this remains to be determined in larger scale trials.
Identification of potential biomarkers will also be important to
identify patient subgroups who may gain particular benefit.
In conclusion, the RBD for xentuzumab was determined to be
1000mg/week and was recommended as the dose for further
clinical evaluation. Clinical development of xentuzumab in
combination with other anti-cancer therapies is feasible based
on its favourable safety profile and biological activity in these
studies. The safety and anti-tumour activity of xentuzumab, as well
as potential biomarkers, is being assessed further in breast and
prostate cancers.
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